Plasma proteins in choroidal vasculature

Plasma proteins in the choroidal vasculature refer to the diverse group of proteins, including albumin, immunoglobulins, and complement factors, that circulate within the blood vessels of the eye's choroid layer (NIH, 2014). Under physiological conditions, the blood-retinal barrier maintains a strict separation, but pathological states like age-related macular degeneration (AMD) and diabetic retinopathy cause these vessels to become hyperpermeable (MDPI, 2021). This breakdown leads to the leakage of plasma proteins into the subretinal space, resulting in edema, fibrin deposition, and the recruitment of inflammatory cells (EntoKey, 2016). Specifically, the extravasation and activation of complement proteins such as C3 and C5 are critical drivers of chronic inflammation and tissue damage in the outer retina (NIH, 2024). While plasma proteins as a collective are not a single drug target, therapeutic intervention focuses on preventing their leakage by inhibiting vascular endothelial growth factor (VEGF) or by directly targeting specific plasma-derived inflammatory mediators like the complement cascade (ARVO, 2024). Consequently, drugs such as ranibizumab and pegcetacoplan are used to manage the consequences of plasma protein dysregulation in the choroidal environment (BMJ, 2024).

Other names

Choroidal plasma proteinsExtravasated plasma proteinsVascular leakage proteinsChoroidal exudate proteins

Inhibition of vascular endothelial growth factor (VEGF) to reduce vascular permeability and prevent the extravasation of plasma proteins; Inhibition of the complement cascade (e.g., C3 or C5) to prevent the deposition and pro-inflammatory activity of plasma-derived complement factors in the choroid.